AbbVie reported Phase 3 success for etentamig, its dual-acting T cell engager for multiple myeloma, meeting the main trial goal to improve outcomes versus standard therapy. Company data indicate a 60% reduction in risk of disease progression or death, based on interim monitoring results that prompted investigators to unblind at a pre-planned checkpoint. The study enrolled 421 patients and compares etentamig to control regimens in people who had progressed after multiple prior lines. AbbVie also highlighted low rates of serious immune-related adverse events characteristic of this drug class and suggested the tolerability profile could support broader delivery outside tightly controlled inpatient monitoring settings. With Tecvayli-style bispecific competition intensifying, etentamig’s Phase 3 performance and safety narrative will be central to how clinicians weigh dosing practicality against depth of response and downstream treatment sequencing.